Navigation Links
Final Approval of Novartis Gender Discrimination Settlement Slated for November 19
Date:11/18/2010

NEW YORK, Nov. 18, 2010 /PRNewswire/ -- The final hearing for approval of the class settlement in the long-running class action gender discrimination case brought by female sales representatives at Novartis Pharmaceutical Corporation is set for Friday, November 19th at 10 a.m. in the courtroom of Judge Colleen McMahon of United States District Court for the Southern District of New York in Manhattan.

The plaintiffs are seeking Court approval for the unopposed final settlement agreement. The settlement terms include the disbursement of $175 million – $152.5M of which includes 100% of back pay, benefits and adjusted wages, compensatory damages, service payments to class representatives and class members who helped prosecute the case, attorneys' fees and case expenses. In addition to the monetary relief, the settlement includes $22.5M of non-monetary relief which Novartis will invest, as required by the terms of the settlement, to engage in substantive programmatic changes to improve employment practices at Novartis. This is believed to be one of the largest non-monetary settlements ever reached.

The plaintiffs are also requesting that the Court approve a final certification of the settlement class, which currently totals some 6,026 women who worked for the pharmaceutical giant during the class period that now extends from July 15, 2002 through July 14, 2010.

"This is an excellent monetary agreement for female sales representatives of Novartis," said Mr. Sanford. "More important, Novartis will be a better company going forward; it is changing its ways and is doing the right thing."

The class is represented by a team of attorneys from Sanford Wittels & Heisler LLP (SWH), a boutique class-action civil rights litigation law firm with offices in New York, Washington, D.C., and San Francisco. The Novartis litigation team is headed by SWH partners David Sanford and Katherine M. Kimpel. The matter has been pending since 2004.

ABOUT SWH

Sanford Wittels & Heisler is a law firm with offices in Washington, D.C., New York, and San Francisco that specializes in employment discrimination, wage and hour, consumer and complex corporate class action litigation and has represented thousands of individuals in some of the major class action cases in the United States. The firm also represents individual clients in employment, employment discrimination, sexual harassment, whistleblower, public accommodations, commercial, medical malpractice, and personal injury matters.


'/>"/>
SOURCE Sanford Wittels & Heisler LLP
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Aegerion Pharmaceuticals, Inc. Presents Final Results of Phase II Clinical Trials for AEGR-733 at Drugs Affecting Lipid Metabolism (DALM) 2007 Conference
2. Daiichi Sankyo and Forest Laboratories Finalize Contract for Co-Promotion of AZOR(TM)
3. Oral Talactoferrin Alfa Improves Overall Survival in Patients With Refractory Non-Small Cell Lung Cancer: Final Phase 2 Study Results Presented at the 8th Annual Targeted Therapies for the Treatment Of Lung Cancer Meeting
4. Nventa Enrolls and Initiates Dosing of Final Cohort in HspE7 Phase 1 Cervical Dysplasia Trial
5. Final Data From the SEISMIC Trial Suggest Safety, Efficacy of Autologous Stem- Cell Therapy for Treating Congestive Heart Failure
6. Final Data From the Bioheart Seismic Trial Suggest Safety, Efficacy of Autologous Stem-Cell Therapy for Treating Congestive Heart Failure
7. Poniard Pharmaceuticals Announces Final Picoplatin Data from Phase 2 Small Cell Lung Cancer Trial Demonstrating Survival Benefit
8. Nventa Completes Safety Evaluation on Final Cohort in HspE7 Phase 1 Cervical Dysplasia Trial
9. Final Results of Ideal Study Presented at Annual Meeting of the European Association for the Study of the Liver (EASL)
10. The Anatomy of Clinical Trials: Greys Season Finale Leaves Public in the Dark About the Myths and Realities
11. Final Results of the CellCept(R) Spare the Nephron (STN) Study Show Maintenance Therapy is Associated with Improved Renal Function
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... , June 24, 2016  Global Blood ... biopharmaceutical company developing novel therapeutics for the treatment ... today announced the closing of its previously announced ... stock, at the public offering price of $18.75 ... offering were offered by GBT. GBT estimates net ...
(Date:6/24/2016)... ALEXANDRIA, Va. , June 24, 2016 ... a set of recommendations that would allow ... information (HCEI) with entities that make formulary and coverage ... determine the "value" of new medicines. The ... that does not appear on the drug label, a ...
(Date:6/24/2016)... PUNE, India , June 24, 2016 ... "Pen Needles Market by Type (Standard Pen Needles, Safety ... 12mm), Therapy (Insulin, GLP-1, Growth Hormone), Mode of Purchase ... published by MarketsandMarkets, This report studies the market for ... is expected to reach USD 2.81 Billion by 2021 ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... June 25, 2016 , ... Experts from the ... AcademyHealth’s Annual Research Meeting June 26-28, 2016, at the Hynes Convention Center in ... topics including advance care planning, healthcare costs and patient and family engagement. , ...
(Date:6/25/2016)... ... 2016 , ... "With 30 hand-drawn hand gesture animations, FCPX users can easily ... of Pixel Film Studios. , ProHand Cartoon’s package transforms over 1,300 hand-drawn pictures ... . Simply select a ProHand generator and drag it above media or text in ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. Calvin Johnson ... Recently, he has implemented orthobiologic procedures as a method for treating his patients. ... the first doctors to perform the treatment. Orthobiologics are substances that orthopaedic surgeons ...
(Date:6/24/2016)... , ... June 24, 2016 , ... A recent ... most people are unfamiliar with. The article goes on to state that individuals are ... many of these less common operations such as calf and cheek reduction. The Los ...
(Date:6/24/2016)... ... ... in a crisis. Her son James, eight, was out of control. Prone to extreme mood ... something upset him, he couldn’t control his emotions,” remembers Marcy. “If there was a ... children and say he was going to kill them. If we were driving on ...
Breaking Medicine News(10 mins):